Voyager Therapeutics/$VYGR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Voyager Therapeutics
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Ticker
$VYGR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
172
ISIN
US92915B1061
Website
VYGR Metrics
BasicAdvanced
$182M
-
-$1.46
0.95
-
Price and volume
Market cap
$182M
Beta
0.95
52-week high
$9.55
52-week low
$2.65
Average daily volume
469K
Financial strength
Current ratio
6.098
Quick ratio
5.922
Long term debt to equity
12.675
Total debt to equity
15.4
Management effectiveness
Return on assets (TTM)
-15.04%
Return on equity (TTM)
-27.61%
Valuation
Price to revenue (TTM)
2.849
Price to book
0.67
Price to tangible book (TTM)
0.67
Price to free cash flow (TTM)
-1.673
Growth
Revenue change (TTM)
-43.75%
Earnings per share change (TTM)
2,162.41%
3-year revenue growth (CAGR)
28.48%
3-year earnings per share growth (CAGR)
-7.98%
What the Analysts think about VYGR
Analyst ratings (Buy, Hold, Sell) for Voyager Therapeutics stock.
VYGR Financial Performance
Revenues and expenses
VYGR Earnings Performance
Company profitability
VYGR News
AllArticlesVideos
Voyager Reports First Quarter 2025 Financial and Operating Results
GlobeNewsWire·4 weeks ago
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
GlobeNewsWire·1 month ago
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Voyager Therapeutics stock?
Voyager Therapeutics (VYGR) has a market cap of $182M as of June 03, 2025.
What is the P/E ratio for Voyager Therapeutics stock?
The price to earnings (P/E) ratio for Voyager Therapeutics (VYGR) stock is 0 as of June 03, 2025.
Does Voyager Therapeutics stock pay dividends?
No, Voyager Therapeutics (VYGR) stock does not pay dividends to its shareholders as of June 03, 2025.
When is the next Voyager Therapeutics dividend payment date?
Voyager Therapeutics (VYGR) stock does not pay dividends to its shareholders.
What is the beta indicator for Voyager Therapeutics?
Voyager Therapeutics (VYGR) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.